CombiMatrix Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 3/3/2017)
| Balance Sheet | Total Assets | 8,478,000.00 | ROE | – |
| Balance Sheet | Total Equity | 6,494,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -157,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -4,057,000.00 | – | – |
| Cashflow | Operating Cash Flow | -3,900,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -3.27 | Div. Yield | – |
| Income | Net Income | -4,140,000.00 | P/E | – |
| Income | Shares Outstanding | 2,560,000.00 | P/B | – |
| Income | Total Revenue | 12,869,000.00 | P/S | – |
Ratios calculated on: –
Company Description
CombiMatrix Corporation is a molecular diagnostics company. The Company operates in the field of genetic analysis and molecular diagnostics through its wholly owned subsidiary, CombiMatrix Molecular Diagnostics, Inc. located in Irvine, California. The Company operates as a diagnostics reference laboratory, providing DNA-based clinical diagnostic testing services to physicians, hospitals, clinics and other laboratories in the areas of pre-and postnatal development disorders and hematology/oncology genomics. The Company´s BAC arrays enable the Company to perform aCGH studies to evaluate genomic alterations. The Company´s oligo arrays allow the Company to perform aCGH on a much more refined scale than is possible with BAC technology. During the year ended December 31, 2011, it also owns a 33% interest in Leuchemix, Inc. (Leuchemix), a private drug development company focused on developing a series of compounds to address a number of oncology-related diseases.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.combimatrix.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more